Navigation Links
goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
Date:1/11/2012

SAN FRANCISCO, Jan. 11, 2012 /PRNewswire/ -- goBalto, developer of new generation web-based clinical research solutions, announced that it successfully completed a FDA 21 CFR Part 11 compliance audit of its goBalto Tracker™ Software-as-a-Service (SaaS) clinical trials application. Tracker's successful audit will help both sponsors / clinical research organizations and investigator sites running clinical trials comply with FDA rules and regulations governing electronic records and electronic signatures.

"The Tracker application demonstrated compliance with the current 21 CFR Part 11 industry standards feature set for security, data transfer, audit trails, and electronic signatures. No deficiencies were found. The implementation of security and electronic signature components is elegant and sets a new standard for web-based GxP applications," said David Nettleton, principal at Computer System Validation, who conducted the audit.

goBalto and David Nettleton found innovative ways to balance 21 CFR Part 11 compliance requirements with cutting-edge Agile software development practices, facilitating rapid response from the feedback of clinical trial professionals.

About goBalto

goBalto is a developer of new generation web-based solutions that simplify how clinical trials are conducted in the pharmaceutical, biotechnology and medical device industries. Tracker™, launched in June 2011, is the first purpose-built Software-as-a-Service clinical research tool that enables clinical trials sponsors and clinical research organizations to collaborate with multiple partners directly from the web in a transparent and regulatory compliant manner. Founded in Silicon Valley in 2008 by biotechnology industry veteran Jae Chung and backed by leading health technology investors, goBalto applies Agile and lean startup methodologies to building technological solutions that address evolving global healthcare. Visit www.gobalto.com for more information.

About David Nettleton:

David Nettleton, principal at Computer System Validation, is an industry leader, author, and teacher for 21 CFR Part 11, Annex 11, HIPAA, software validation, and computer system validation. He is involved with the development, purchase, installation, operation and maintenance of computerized systems used in FDA compliant applications. His most popular book is Risk Based Software Validation – Ten easy Steps (Davis Horwood International and PDA – www.pda.org, 2006), which provides fill-in-the-blank templates for completing a COTS software validation project. He has completed more than 205 mission critical laboratory, clinical, and manufacturing software implementation projects.

 


'/>"/>
SOURCE goBalto
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. goBalto Introduces Web-based Solution to Manage Drug-development Collaborations
2. goBalto Drug Development Partnering WebSite to Include Clinical Trials Support's List of Investigator Sites
3. goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites
4. MiMedx Group Completes $5,000,000 Private Placement
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. CeNeRx BioPharma Completes $4.85 Million Financing
7. Aratana Therapeutics Completes $15 Million Series B Financing
8. InnoPharma Completes $15 Million Series A Financing
9. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
10. Agendia Successfully Completes Bi-Annual FDA Inspection
11. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 /PRNewswire/ ... the formation of its Medical/Clinical Advisory Board.  This ... veterans who enhance the range and depth of ... of its novel prenatal diagnostic tests.  These experts ... strategic guidance for the company,s product development and ...
(Date:1/19/2017)... and GAITHERSBURG, Md. ... MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics ... of a definitive agreement for the merger of ... current investors include Novartis Venture Fund, HealthCap, Truffle ... be a fully-integrated and diversified immunotherapeutics company with ...
(Date:1/19/2017)... Staten Island, NY (PRWEB) , ... January 19, 2017 , ... ... expand at an exponential rate. The tremendous growth is accounted to two main ... to the table and the expanding network of vendors supplying FireflySci products all around ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
Breaking Biology Technology:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
Breaking Biology News(10 mins):